Influenza A virus H5N6 surface antigens (H5N6 antigens)

Influenza A virus H5N6 surface antigens, primarily comprising the glycoproteins Hemagglutinin (H5) and Neuraminidase (N6), are the critical molecular targets for prophylaxis and treatment of H5N6 avian influenza. Hemagglutinin facilitates viral infection by mediating binding to alpha-2,3-linked sialic acid receptors on host cells and subsequent membrane fusion, while Neuraminidase is an enzyme essential for the release of new viral particles from the host cell surface [1][3]. As H5N6 is a highly pathogenic avian influenza (HPAI) strain with significant zoonotic potential, these antigens are the focus of international surveillance and the development of candidate vaccine viruses (CVVs) [2][4]. In therapeutic contexts, the N6 protein is targeted by neuraminidase inhibitors such as oseltamivir to curtail viral spread within the respiratory tract. However, the high rate of mutation in the HA and NA genes necessitates continuous monitoring for antigenic drift, which can render existing vaccines and monoclonal antibodies ineffective [2][5]. Understanding the structural biology of these antigens is vital for developing next-generation universal flu vaccines and maintaining pandemic preparedness against emerging H5N6 lineages [4][6].

Other names

H5N6 Hemagglutinin and NeuraminidaseA(H5N6) viral proteinsAvian influenza H5N6 antigensH5N6 HA/NA

Neuraminidase inhibitors (e.g., oseltamivir, zanamivir) competitively inhibit the N6 neuraminidase enzyme, preventing the cleavage of sialic acid residues and thus blocking the release of progeny virions from infected host cells [1][2]. Hemagglutinin (H5) targeted vaccines or antibodies bind to the HA1 subunit, sterically hindering the interaction between the virus and host cell sialic acid receptors, thereby neutralizing viral entry [3][5]. Cap-dependent endonuclease inhibitors (e.g., baloxavir) target the polymerase complex to inhibit viral mRNA synthesis, though HA and NA remain the primary surface antigenic targets [1].